Skip to main content
. 2013 Jun 4;110(25):E2298–E2307. doi: 10.1073/pnas.1301838110

Table 1.

CGP57380 inhibits the ability of primary BC progenitors to serially replate

BC CML DMSO, % CGP57380 IM, % Dasatinib, %
CML 1 39.5 ND 11 14.2
CML 2 7.1 ND 3.9
CML 3* 51.7 ND 37.5
CML 4 10.8 ND 7.1
CML 5 11.8 ND 4.3
CML 6* 53.2 ND 75 45.8
CML7 35.2 ND 35.6 39.9
CML11 70.0 ND 40.0

CD34+ BC cells from eight different individuals with BC were treated with DMSO, 10.0 μM CGP57380, 2.0 μM IM, or 150 nM dasatinib for 48 h before harvesting for the CFC assay, and subsequent serial replating assay. Values presented here represent the third serial replating efficiency relative to the first CFC readout. ND, no colonies detected.

*

BC CML samples harboring the T315I mutation.

HHS Vulnerability Disclosure